Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed EBITDA for 3 consecutive years, with -$40.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 203.37% to -$40.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.4 million through Dec 2025, down 55.25% year-over-year, with the annual reading at -$80.4 million for FY2025, 55.25% down from the prior year.
  • EBITDA hit -$40.3 million in Q4 2025 for Camp4 Therapeutics, down from -$15.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$11.7 million in Q3 2023 to a low of -$40.3 million in Q4 2025.
  • Historically, EBITDA has averaged -$15.7 million across 3 years, with a median of -$12.8 million in 2023.
  • Biggest YoY gain for EBITDA was 0.15% in 2025; the steepest drop was 203.37% in 2025.
  • Year by year, EBITDA stood at -$13.0 million in 2023, then fell by 2.22% to -$13.3 million in 2024, then crashed by 203.37% to -$40.3 million in 2025.
  • Business Quant data shows EBITDA for CAMP at -$40.3 million in Q4 2025, -$15.1 million in Q3 2025, and -$12.6 million in Q2 2025.